Philadelphia Startup Licensed Anti-IL-33 Drug for Trials
Tolerance Bio acquired the asset from Tanabe Pharma to restore thymic function and improve immune resilience.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust that biotech companies prioritize medical innovation over their own financial returns?
Philadelphia-based Tolerance Bio has licensed the monoclonal antibody MT-2990, now rebranded as TLB-33, from Tanabe Pharma for development outside of Japan. The company plans to initiate a Phase 2 study for the drug, which aims to block IL-33 signaling.
Why it matters
The development aims to mitigate thymic involution, where the thymus gland shrinks, by preserving its function through the modulation of IL-33 inflammatory signaling. This approach represents an effort to maintain immune resilience in patients.
The licensing agreement includes potential milestone payments of $560 million, following Tolerance Bio’s previous $260 million licensing deal for an IL-7 fusion protein. The drug functions by blocking IL-33 signaling, a pathway known to drive thymic involution in inflammatory environments.
The players
Tolerance Bio
A Philadelphia-based biotechnology startup focused on immune resilience that launched in 2024 with $17.2 million in seed funding.
Tanabe Pharma
A pharmaceutical company that conducted the initial five clinical trials for the drug currently known as MT-2990.
The details
TLB-33 is a monoclonal antibody, a laboratory-produced molecule engineered to bind to specific antigens, designed to inhibit the IL-33 signaling pathway. By blocking this signaling, the therapy seeks to prevent the degradation of the thymus, the organ responsible for T-cell maturation. The clinical foundation for this transition includes data from 150 patients across five previous trials conducted by Tanabe Pharma.
Timeline
October 2024: Tolerance Bio launched with $17.2 million in seed funding.
August 2026: Tolerance Bio licensed an IL-7 fusion protein.
September 28, 2026: Tolerance Bio announced the Tanabe Pharma licensing deal.
The Tech Race
This deal expands the pipeline of Tolerance Bio following their previous $260 million investment in IL-7 fusion protein technology. The company is now positioning itself to address thymic function through dual pathways of immune resilience.
This development moves a therapy from past clinical trials into a new Phase 2 study, shifting the drug toward potential future clinical availability. Patients and practitioners should watch for the initiation of these trials to determine which specific inflammatory conditions are eligible for treatment.
The takeaway
Tolerance Bio is attempting to scale its immune-resilience platform by targeting a second cytokine pathway after its initial IL-7 investment. Watch for the company's next financing round and the formal protocol registration for the upcoming Phase 2 trial of TLB-33.
What happens next
Tolerance Bio plans to initiate a Phase 2 study for TLB-33 and has stated intentions for an upcoming financing round to support these future trials.
Further reading
For more on local research initiatives, visit the Biotech section.
Live Poll
Do you trust that biotech companies prioritize medical innovation over their own financial returns?
